Nanobiotix S.A. filings document foreign private issuer reporting for a late-stage clinical biotechnology company developing nanoparticle-based therapeutic platforms. Recent Form 6-K reports furnish press-release exhibits covering JNJ-1900 (NBTXR3) clinical and regulatory disclosures, Nanoprimer preclinical data, operating and financial updates, and responses to corporate-status speculation.
The filing record also documents capital-structure and governance information, including share capital, theoretical and exercisable voting rights reported under French market rules, material agreements tied to development and commercialization collaborations, and foreign private issuer status on Form 20-F for its Euronext Paris and Nasdaq-listed securities.
Nanobiotix S.A. reported final data from a Phase 1 study of JNJ-1900 (NBTXR3) with radiotherapy followed by nivolumab or pembrolizumab in 24 patients with anti-PD-1-resistant advanced primary cutaneous melanoma. The overall response rate was 41.7% (10 of 24 patients), including four complete responses; the disease control rate was 75% (18 of 24). Median progression-free survival was 6.9 months and median overall survival was 17.8 months.
Investigators reported an acceptable safety profile, with no new safety signals observed. In an exploratory analysis of plasma samples from eight patients, IL-1β showed the largest increase from baseline among the cytokines evaluated. The company described the findings as preliminary and said they warrant evaluation in larger randomized trials.
Nanobiotix S.A. reported 50,967,610 shares outstanding as of September 30, 2026, alongside 54,729,543 total theoretical voting rights and 54,707,425 total exercisable voting rights. The theoretical figure includes shares with voting rights suspended; the exercisable figure excludes shares held in treasury whose voting rights are suspended.
Nanobiotix S.A. (NBTX) appointed Arnd Christ as chief financial officer and a member of its executive board, effective October 1, 2026. He succeeds Bart Van Rhijn, who will step down as chief financial and business officer and executive board member after five years with the company.
Christ has more than 25 years of financial leadership experience at public and private biotechnology companies in Europe and the United States. Most recently, he served as chief financial officer of Immatics N.V. from October 2020 until September 2025. He previously held CFO roles at several European biotechnology companies, including InflaRx, MediGene, NovImmune and Probiodrug.
Nanobiotix S.A. reported unaudited first-half 2026 revenue and other income of €5.551 million, versus €26.638 million; 2025 included €21.2 million of one-off revenue from a Janssen agreement modification. Operating expenses were €23.475 million versus €25.829 million. Operating result was a loss of €17.924 million versus income of €0.808 million, and net loss was €34.288 million versus €5.383 million. Interest costs were €14.5 million, up from €4.2 million, mainly on royalty financing.
Cash and cash equivalents were €110.9 million as of June 30, 2026, which Nanobiotix expects to fund operations beyond the next 12 months. The May 26, 2026 global offering generated approximately $100 million (€86.1 million) in gross proceeds and €80.1 million in net proceeds, from 2,218,467 ordinary shares and 345,099 pre-funded warrants. The company intends to use less than 10% of net proceeds for JNJ-1900, 50–60% for Nanoprimer and other platforms, and 30–40% for general corporate purposes.
In CONVERGE Phase 2 Part 1, investigator-reported ORR was 85.7% (6/7) and the complete response rate was 57.1% (4/7), compared with 71.4% (5/7) and no complete responses at the earlier assessment. The updated data were presented at ESTRO 2026.
Nanobiotix S.A. reported first-half 2026 results, with €110.9 million in cash and cash equivalents as of June 30, 2026. Revenue and other income totaled €5.6 million, versus €26.6 million in first-half 2025; that period included a €21.2 million one-time, non-cash impact from transferring NANORAY-312 sponsorship to Johnson & Johnson. Net loss attributable to common shareholders was €34.3 million versus €5.4 million in first-half 2025.
The company completed a May 2026 follow-on offering generating approximately €86 million in gross proceeds and anticipates cash will fund operations into 2029 under its current operating plan and financial projections. In an MD Anderson-sponsored Phase 1 NSCLC study, all 24 patients completed treatment without dose-limiting toxicities; at a median follow-up of 12 months, one-year locoregional control was 79%. In Johnson & Johnson-led Phase 2 CONVERGE, investigator-reported overall and complete response rates were 85.7% (6/7) and 57.1% (4/7). The FDA cleared a NANORAY-312 amendment that eliminated the planned interim analysis and modified the final analysis to include fewer events than originally planned, for earlier conduct.
Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of August 31, 2026. The company had 50,941,528 shares outstanding, corresponding to 54,701,246 theoretical voting rights and 54,679,128 exercisable voting rights, in line with French disclosure requirements for tracking shareholder threshold crossings.
Nanobiotix S.A. (NBTX) reported full Phase 1 cohort results for radiotherapy-activated JNJ-1900 (NBTXR3) in 24 patients with inoperable, locoregionally recurrent non-small cell lung cancer eligible for re-irradiation. All patients completed treatment with no dose-limiting toxicities and no Grade 3 or higher adverse events related to JNJ-1900 or the injection procedure, and intratumoral injection was deemed feasible.
At a median follow-up of 12 months, one-year locoregional control was 79%, one-year local progression-free survival was 61% (median 13.6 months), and one-year overall survival was 70% (median 14.8 months), achieved with re-irradiation doses lower than patients’ prior radiotherapy. Grade 3 radiotherapy-related adverse events occurred in 33% of patients and Grade 5 radiotherapy-related events in 8%. Investigators set the recommended Phase 2 dose at 33% of gross tumor volume and concluded JNJ-1900 (NBTXR3) may support clinically meaningful local control at substantially lower re-irradiation doses, warranting evaluation in a randomized trial and further enrollment.
Nanobiotix S.A. (NBTX), a late-stage clinical biotechnology company, reported that its management will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference in New York on September 15, 2026 at 12:00 pm EDT / 6:00 pm CEST.
The session will feature Chief Executive Officer Laurent Lévy and Chief Financial and Business Officer Bart Van Rhijn. Nanobiotix highlights its portfolio of more than 30 umbrella patents across three nanotechnology platforms in oncology, bioavailability and biodistribution, and central nervous system disorders.
Nanobiotix S.A. (NBTX) reported its share capital and voting rights position as of July 31, 2026, in line with articles L.233-8 II of the French Commercial Code and article 223-16 of the General Regulation of the French Financial Markets Authority. The company had 50,833,462 shares outstanding. Total theoretical voting rights were 54,534,179, while total exercisable voting rights at shareholder meetings were 54,512,061, reflecting the exclusion of shares with suspended voting rights such as treasury shares. Nanobiotix remains listed on Euronext Paris and the Nasdaq Global Select Market.
Nanobiotix S.A. has an institutional holder group led by Invus Public Equities, L.P. reporting beneficial ownership of 4,483,275 ordinary shares and 345,099 pre-funded warrants, each exercisable for one share at Euro 0.03 per share and expiring May 26, 2036. Based on 50,807,903 shares outstanding as of May 31, 2026, plus the warrant shares, the Invus-related reporting persons each may be deemed to beneficially own 4,828,374 shares, or 9.4% of the company. The group reports sole voting and dispositive power over these securities and certifies that the holdings are not for the purpose of changing or influencing control. Nanobiotix ADSs, each representing one ordinary share, trade under the symbol NBTX and use CUSIP 63009J107.